Marking its global debut at EPS - the Activo-P11 Peptide Synthesiser is an easy to use and affordable instrument for synthesis of very high quality peptides
At the recent 29th European Peptide Symposium (EPS) held in Gdansk, Poland, Activotec reported high visitor traffic drawn by the international launch of its Activo-P11 Peptide Synthesiser and a poster reporting on proprietary techniques in peptide backbone modification used to develop modified GLP-1 analogues.
Designed and manufactured in Europe the new fully automated and enclosed system performs a wide range of chemistries to synthesise peptides of any length in the 0.1-1.0mmol scale.
Combined with very easy-to-use software, designed by chemists for chemists, the Activo-P11 was one of the most visited attractions at the exhibition.
Particular interest was also shown in a new technical poster describing a study in which it Activotec had applied its proprietary technologies in peptide backbone modification to develop a set of modified GLP-1 analogues which have been stabilised against proteolysis, yet are at least as active as native GLP-1 in both promoting insulin release in cell assays and lowering blood glucose in small animal models.
These exciting results drew considerable attention from biotech and pharmaceutical industry researchers involved in the diabetes therapeutic area.
Other products on show included the recently introduced PLS organic synthesiser - an easy-to-use and affordable tool for parallel solution and solid phase chemistry.
Activotec, which has its trading base in Cambridge (UK) and an R+D and production facility in Southampton (UK), was founded in 2002 as a spin out from the internationally renowned School of Biological Sciences at the University of Southampton.
Activotec is a customer-focused company providing high technology products and services for chemistry and biochemistry applications.
Activotec provides a complete range of products and services for peptide and protein synthesis.
